Treatment Outcomes and Prognostic Factors for Patients With Medulloblastoma Having Defined Molecular Subtypes.

ABSTRACT: This study aims to evaluate treatment outcomes and prognostic factors in pediatric patients with medulloblastoma (MB) with defined molecular subtypes to inform subsequent individualized treatment. A retrospective analysis was conducted on 145 patients with MB with defined molecular subtypes who underwent radiation therapy (RT) at our institution from January 2017 to 2021. Patients were subjected to traditional clinical risk stratification, molecular risk stratification, and National Comprehensive Cancer Network (NCCN) risk stratification, respectively. The treatment outcomes and associated prognostic factors were analyzed. With a median follow‑up of 49 months, the 5-year event-free survival (EFS) and overall survival rates were 68.6% ± 4.0% and 74.7% ± 4.4%, respectively. Multivariate anal

SUBMITTER: Shi X 

PROVIDER: S-EPMC12361598 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature